Postoperative PainPhase 4NCT03064633
Dexamethasone Versus Dexmedetomidine
A Phase 4 study testing dexamethasone 8 mg, dexmedetomidine 80 µg and Bupivacaine 0.25% Injectable Solution in people with Postoperative Pain, run by Fayoum University Hospital at 1 site in Egypt.
Trial summary
The transversus abdominis plane (TAP) block is most often used to provide surgical anesthesia for minor, superficial procedures on the lower abdominal wall, or postoperative analgesia for procedures below the umbilicus providing anesthesia to the ipsilateral lower abdomen below the umbilicus. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Postoperative Pain
- What is being tested?
- dexamethasone 8 mg, dexmedetomidine 80 µg and Bupivacaine 0.25% Injectable Solution
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 1 siteEgypt
- Study dates
- 8 Mar 2017to 30 Apr 2018
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- American society of anesthesiologists (ASA) physical status grade 1 and 2.
- Age of 18 years and more.
- Patients who will be scheduled for total abdominal hysterectomies.
Who cannot join
- Patient refusal.
- Body mass index (BMI) > 40.
- Patients with chronic pain and those using chronic analgesic medications.
- Coagulopathy.
- Allergy to the study drugs.
- Patients taking other medications with α-adrenergic blocking effect.
Show all 9Show fewer
- Hepatic or renal insufficiency.
- Systemic infection.
- Infection at the site of injection.
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Fayoum University hospital
El Fayoum Qesm, Faiyum Governorate, 63514
About this study
Official title: Dexamethasone Versus Dexmedetomidine as Local Anesthetic Adjuvants in Ultrasound Guided Transversus Abdominis Plane Block for Total Abdominal Hysterectomies
The transversus abdominis plane (TAP) block is most often used to provide surgical anesthesia for minor, superficial procedures on the lower abdominal wall, or postoperative analgesia for procedures below the umbilicus providing anesthesia to the ipsilateral lower abdomen below the umbilicus.
In a recent meta-analysis, the TAP block was shown to reduce the need for postoperative opioid use, increase the time to the first request for further analgesia, and provide more effective pain relief, while decreasing opioid-related side effects such as sedation and postoperative nausea and vomiting. The provision of effective postoperative analgesia is of key importance to facilitate early ambulation and prevention of postoperative morbidity. The analgesic regimen needs to meet the goals of providing safe, effective analgesia, with minimal side effects. Many additives to local anesthetics used to prolong the duration of analgesia for peripheral nerve blocks have been studied as dexamethasone, dexmedetomidine Dexmedetomidine is a lipophilic α2 agonist derivative with a higher affinity for α2-receptors than clonidine (α2: α1 specificity ratio is 200:1 for clonidine and 1600:1 for dexmedetomidine). It has sedative, analgesic, and sympatholytic effects that blunt many of the cardiovascular responses seen during the perioperative period. Animal and human studies have shown safety and efficacy of adding dexmedetomidine to local anesthetics in various regional anesthetic procedures. The addition of dexmedetomidine to bupivacaine in TAP block achieves better local anesthesia and provides better pain control postoperatively without any major side-effects.
Read more
Dexamethasone is a systemic glucocorticoid that improves the quality of recovery after surgery by reducing pain, nausea, and vomiting. When added to local anesthetics as an adjuvant in peripheral blocks, it prolongs the analgesia time. Mechanism of action may be through the anti-inflammatory action, the increase of the local efficiency, and to slow down of the absorption.
Objective:
The objective is to compare and evaluate efficacy and safety of dexmedetomidine and dexamethasone as a local anesthetic adjuvant to bupivacaine in ultrasound-guided TAP block for patients scheduled for total abdominal hysterectomies.
Read the detailed description
PATIENTS AND METHODS:
This study will be performed on Fifty-four adult patients who will be undergone an abdominal hysterectomy after obtaining the approval of the local ethical committee and scientific institutional review board. written informed consents will be signed from each patient before enrollment and randomization into the study.
The patients will be randomly allocated to receive either a mixture of bupivacaine and dexamethasone 8 mg (group A, 27 patients) or a mixture of bupivacaine and dexmedetomidine 80 µg (group B, 27 patients). Randomization will be performed by using a computer-generated random number list. The random number for each patient will be concealed in opaque sealed envelope which will be opened by the investigators shortly after the admission of the patient into the operation room. The investigators sharing in the patients care and data acquisition will be blinded to groups allocation till full completion of statistical analysis.
Preoperative preparation:
Visual analog scale (VAS) will be explained to all the patients on preoperative visit (0-10 cm, in which 0 cm = no pain and 10 cm = worst pain) and the compulsory investigations according to the regular institutional protocol will be done [electrocardiogram (ECG), complete blood count (CBC), blood sugar level, serum urea and creatinine, liver function tests, and coagulation profile].
On the day of surgery, intravenous (IV) access will be inserted. The patient will be administered midazolam 0.03 mg/kg, metoclopramide 10 mg slowly, ranitidine 50 mg, and cefotaxime 1 gm intravenously (IV) as premedications.
Anesthetic technique:
All the patients will be received a standard general anesthesia with standard monitoring [ECG, noninvasive blood pressure (NIBP), capnography and pulse oximetry]. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg and Atracurium 0.5 mg/kg will be used for muscle relaxation to facilitate endotracheal intubation by cuffed endotracheal tube (internal diameter = 7 mm).
After induction of anesthesia and under a complete aseptic condition, the TAP blocks will be performed by the attending anesthesiologists who will not participate in this trial under real-time ultrasound guidance (Philips ClearVue 350 Ultrasound Machine, Philips healthcare, USA). At the level of the umbilicus, the high-frequency ultrasound linear array probe (L4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. Identification of the external oblique, the internal oblique, and the transversus abdominis muscles and localization of the fascial plane between the internal oblique and the transversus abdominis muscle that appeared as a hypoechoic line will be done. The local anesthetic solution mixture will be injected with short bevel needle (22 Gauge, 90 mm sonoplex stim cannula, Pajunk® GmbH, Geisingen, Germany) under real-time ultrasound guidance after negative aspiration to avoid intravascular injection. The local anesthetic solution mixture will be observed separating the fascial plane during injection. The TAP block will be then performed on the opposite side, using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to group A (dexamethasone group, 27 patients), the local anesthetic solution mixture consisted of a total volume of 40 ml bupivacaine 0.25 % and dexamethasone 8 mg, 20 ml injected on each side. Dexamethasone sodium phosphate (Epidron®, EIPICO, Cairo, Egypt) is supplied in 4 mg/ml ampule. For the patients randomized to group B (dexmedetomidine group, 27 patients), the local anesthetic solution mixture consisted of a total volume of 40 ml bupivacaine 0.25 % and dexmedetomidine 80 µg, 20 ml injected on each side. Dexmedetomidine hydrochloride (Precedex®, manufactured by Hospira, Inc. Lake Forest, IL, and USA) is supplied in 100 μg/ml ampule. the local anesthetic solution mixture will be prepared and coded by independent attending anesthesiologists who will not share in data collection or in patients care.
Anesthesia will be maintained with isoflurane 1.5 volume % and Atracurium 0.1 mg/kg will be administered as a maintenance dose every 30 minutes until completion of the procedure. Ventilation parameters will be adjusted as follows: tidal volume (TV) = 4-8 ml/kg, positive end-expiratory pressure (PEEP) = 5 cm H2O, respiratory rate (RR) = 12/min then it will be adjusted to maintain end-tidal CO2 between 35-40 mmHg, and fraction of inspired oxygen (FiO2) = 0.5-0.6.
Fentanyl 0.5μg/kg will be given intraoperatively when either heart rate or NIBP increased by more than 20% of the basal records and could be repeated till the desired effect. After completion of the procedure, anesthesia will be discontinued and tracheal extubation will be done once the extubation criteria will be fulfilled. The patients then will be transferred to the post-anesthesia care unit (PACU) for two hours' observation period. The patients will be discharged to the ward after fulfilling the discharge criteria based on modified Aldrete score ≥ 9.(17) As a part of standardized regular institutional postoperative pain control policy, Acetaminophen 1 gm every 6 hours by IV infusion and ketorolac 30 mg diluted in 100 ml normal saline through IV infusion over 20 minutes every 8 hours will be administered. Patients with VAS ≥ 5 received morphine sulfate IV at a bolus dose of 2-5 mg increments with a maximum dose of 15 mg per 4 hours or 45 mg per 24 hours. The criteria to stop morphine titration will be reasonable pain control or the patient became sedated (Ramsay sedation scale >2). Furthermore, respiratory rate < 10 / min, Oxygen saturation < 95%, or development of serious adverse effects (allergy, marked itching, excessive vomiting, and hypotension with systolic blood pressure ≤ 20% of baseline readings).
STATISTICAL ANALYSIS:
The normally distributed numerical data will be presented as mean (SD) and differences between groups will be compared using Student's t-tests. Continuous data with skewness and kurtosis as well as the ordinal data will be presented as median (interquartile range[IQR]) and compared for significance by using the Mann-Whit¬ney U test. The Kolmogorov-Smirnov test will be implemented to check the normality of Continuous data distribution (P ≤ 0.05). Categorical data will be presented as proportions and will be compared for significance by using the chi-square test. Fisher's exact test will be used instead if the minimum expected cell count less than five. We will use the log-rank test and Kaplan-Meier curves to compare data measuring time to an event. The level P ≤ 0.05 will be considered the cut-off value for significance. Statistical analysis will be performed using the statistical package for the social sciences (SPSS) version 16 (SPSS Inc., Chicago, IL, USA).
The sample size of 22 patients per group was found acceptable to detect a difference of 65 minutes between both groups in time for the first request of analgesia (primary outcome), assuming α = 0.05 (two tail), β = 0.2 (80 % power), and the standard deviation = 75 minutes (derived from Ammar et al. 2012). Recruitment of 27 patients per group will be done to account for possible data loss. Sample size calculation will be done by using G*Power software version 3.1.9.2 (Institute of Experimental Psychology, Heinrich Heine University, Dusseldorf, Germany).
- Conditions
- Postoperative Pain
- Being tested
- dexamethasone 8 mg, dexmedetomidine 80 µg, Bupivacaine 0.25% Injectable Solution
- Keywords
- Dexamethasone, Dexmedetomidine, Transversus abdominis plane block, Local anesthetic adjuvants, postoperative pain
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
dexamethasone 8 mgDrug
Also called Dexamethasone 4 mg/ml
At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both side using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexamethasone group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexamethasone 8 mg.
dexmedetomidine 80 µgDrug
Also called precedex 100 µg/ml
At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both sides using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexmedetomidine group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexmedetomidine 80 µg.
Bupivacaine 0.25% Injectable SolutionDrug
Also called Marcaine 0.25%
38 ml of the solution will be prepared to be used in transversus abdominis plane block
| Study group | Role | What they receive |
|---|---|---|
| Dexamethasone arm (group A) | Active comparator | The local anesthetic solution mixture consists of dexamethasone 8 mg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 2 ml dexamethasone = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia. Receives: Drug: dexamethasone 8 mg; Drug: Bupivacaine 0.25% Injectable Solution |
| Dexmedetomidine arm (group B) | Active comparator | The local anesthetic solution mixture consists of dexmedetomidine 80 µg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 80 µg dexmedetomidine in 2 ml = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia. Receives: Drug: dexmedetomidine 80 µg; Drug: Bupivacaine 0.25% Injectable Solution |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to first request of analgesia
The time passed till the patient request an analgesic dose
Measured: During the 24 hours postoperatively
Secondary outcomes (36)
Visual Analog Scale (VAS) at rest
Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain
Measured: Assesment will be done at 2 hours postoperatively
Visual Analog Scale (VAS) at rest
Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain
Measured: Assesment will be done at 4 hours postoperatively
Visual Analog Scale (VAS) at rest
Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain
Measured: Assesment will be done at 6 hours postoperatively
Visual Analog Scale (VAS) at rest
Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain
Measured: Assesment will be done at 12 hours postoperatively
Visual Analog Scale (VAS) at rest
Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain
Measured: Assesment will be done at 18 hours postoperatively
Visual Analog Scale (VAS) at rest
Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain
Measured: Assesment will be done at 24 hours postoperatively
Visual Analog Scale (VAS) at rest
Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain
Measured: Assesment will be done at 48 hours postoperatively
Visual Analog Scale (VAS) on movement
Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain
Measured: Assesment will be done at 2 hours postoperatively
Visual Analog Scale (VAS) on movement
Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain
Measured: Assesment will be done at 4 hours postoperatively
Visual Analog Scale (VAS) on movement
Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain
Measured: Assesment will be done at 6 hours postoperatively
Visual Analog Scale (VAS) on movement
Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain
Measured: Assesment will be done at 12 hours postoperatively
Visual Analog Scale (VAS) on movement
Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain
Measured: Assesment will be done at 18 hours postoperatively
Visual Analog Scale (VAS) on movement
Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain
Measured: Assesment will be done at 24 hours postoperatively
Visual Analog Scale (VAS) on movement
Range from 0-10 cm, in which 0 cm=no pain and 10 cm=worst pain
Measured: Assesment will be done at 48 hours postoperatively
Interval doses of consumed morphia
Morphine doses consumed at different times
Measured: During 0 - 2 hours postoperatively
Interval doses of consumed morphia
Morphine doses consumed at different times
Measured: During 2 - 4 hours postoperatively
Interval doses of consumed morphia
Morphine doses consumed at different times
Measured: During 4 - 6 hours postoperatively
Interval doses of consumed morphia
Morphine doses consumed at different times
Measured: During 6 - 12 hours postoperatively
Interval doses of consumed morphia
Morphine doses consumed at different times
Measured: During 12 - 18 hours postoperatively
Interval doses of consumed morphia
Morphine doses consumed at different times
Measured: During 18 - 24 hours postoperatively
Interval doses of consumed morphia
Morphine doses consumed at different times
Measured: During 24 - 48 hours postoperatively
Cumulative doses of consumed morphia
Total morphine doses consumed during the 24 hours postoperatively.
Measured: During the 24 hours postoperatively
Intraoperative fentanyl consumption
total doses of fentanyl consumed during the surgical procedure intraoperatively.
Measured: At the end of surgical procedure
Nausea
incidence of nausea
Measured: During the 48 hour postoperatively
Vomiting
incidence of vomiting
Measured: During the 48 hour postoperatively
Sedation score
Degree of sedation: where:1= Fully awake and oriented, 2= Drowsy, 3= Eye closed but responds to commands, 4= Eye closed but responds to mild physical stimulation, 5= Eye closed and not responding to mild physical stimulation
Measured: At 2 hours postoperatively
Sedation score
Degree of sedation: where:1= Fully awake and oriented, 2= Drowsy, 3= Eye closed but responds to commands, 4= Eye closed but responds to mild physical stimulation, 5= Eye closed and not responding to mild physical stimulation
Measured: At 4 hours postoperatively
Sedation score
Degree of sedation: where:1= Fully awake and oriented, 2= Drowsy, 3= Eye closed but responds to commands, 4= Eye closed but responds to mild physical stimulation, 5= Eye closed and not responding to mild physical stimulation
Measured: At 6 hours postoperatively
Sedation score
Degree of sedation: where:1= Fully awake and oriented, 2= Drowsy, 3= Eye closed but responds to commands, 4= Eye closed but responds to mild physical stimulation, 5= Eye closed and not responding to mild physical stimulation
Measured: At 12 hours postoperatively
Sedation score
Degree of sedation: where:1= Fully awake and oriented, 2= Drowsy, 3= Eye closed but responds to commands, 4= Eye closed but responds to mild physical stimulation, 5= Eye closed and not responding to mild physical stimulation
Measured: At 18 hours postoperatively
Sedation score
Degree of sedation: where:1= Fully awake and oriented, 2= Drowsy, 3= Eye closed but responds to commands, 4= Eye closed but responds to mild physical stimulation, 5= Eye closed and not responding to mild physical stimulation
Measured: At 24 hours postoperatively
Sedation score
Degree of sedation: where:1= Fully awake and oriented, 2= Drowsy, 3= Eye closed but responds to commands, 4= Eye closed but responds to mild physical stimulation, 5= Eye closed and not responding to mild physical stimulation
Measured: At 48 hours postoperatively
Hypotension
incidence of hypotension (systolic blood pressure < 90 mmHg)
Measured: During intraoperative period
Hypotension
incidence of hypotension (systolic blood pressure < 90 mmHg)
Measured: During 48 hours postoperatively
Bradycardia
Incidence of bradycardia ( heart rate < 60 beat/minute)
Measured: During intraoperative period
Bradycardia
Incidence of bradycardia ( heart rate < 60 beat/minute)
Measured: During 48 hours postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2017
- Study start8 Mar 2017
- Primary completion28 Apr 2018
- Study completion30 Apr 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Postoperative PainStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- Fayoum University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hany Mahmoud Yassin, Fayoum University Hospital
- Investigators
- Hany M Yassin, MD, Principal investigator, Fayoum University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03064633
- Sponsor's protocol ID
- M88
- Status last verified
- Jun 2018
- First submitted
- 6 Feb 2017
- Last updated
- 6 Jun 2018
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Ammar AS, Mahmoud KM. Effect of adding dexamethasone to bupivacaine on transversus abdominis plane block for abdominal hysterectomy: A prospective randomized controlled trial. Saudi J Anaesth. 2012 Jul;6(3):229-33. doi: 10.4103/1658-354X.101213.
PubMed 23162395Almarakbi WA, Kaki AM. Addition of dexmedetomidine to bupivacaine in transversus abdominis plane block potentiates post-operative pain relief among abdominal hysterectomy patients: A prospective randomized controlled trial. Saudi J Anaesth. 2014 Apr;8(2):161-6. doi: 10.4103/1658-354X.130683.
PubMed 24843325Abdallah FW, Brull R. Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis. Br J Anaesth. 2013 Jun;110(6):915-25. doi: 10.1093/bja/aet066. Epub 2013 Apr 15.
PubMed 23587874Gadsden J, Ayad S, Gonzales JJ, Mehta J, Boublik J, Hutchins J. Evolution of transversus abdominis plane infiltration techniques for postsurgical analgesia following abdominal surgeries. Local Reg Anesth. 2015 Dec 10;8:113-7. doi: 10.2147/LRA.S96253. eCollection 2015.
PubMed 26677342
Study at a glance
From the registry record, last updated by the sponsor on 6 Jun 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Dexamethasone Versus Dexmedetomidine as Local Anesthetic Adjuvants in Ultrasound Guided Transversus Abdominis Plane Block for Total Abdominal Hysterectomies
- ClinicalTrials.gov ID
- NCT03064633
- Acronym / sponsor ID
- M88
- Conditions
- Postoperative Pain
- Keywords
- Dexamethasone, Dexmedetomidine, Transversus abdominis plane block, Local anesthetic adjuvants, postoperative pain
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- Fayoum University HospitalUniversity, hospital or other
- Study start
- 8 Mar 2017 (actual)
- Primary completion
- 28 Apr 2018 (actual)
- Study completion
- 30 Apr 2018 (actual)
- First posted
- 27 Feb 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The transversus abdominis plane (TAP) block is most often used to provide surgical anesthesia for minor, superficial procedures on the lower abdominal wall, or postoperative analgesia for procedures below the umbilicus providing anesthesia to the ipsilateral lower abdomen below the umbilicus.
In a recent meta-analysis, the TAP block was shown to reduce the need for postoperative opioid use, increase the time to the first request for further analgesia, and provide more effective pain relief, while decreasing opioid-related side effects such as sedation and postoperative nausea and vomiting. The provision of effective postoperative analgesia is of key importance to facilitate early ambulation and prevention of postoperative morbidity. The analgesic regimen needs to meet the goals of providing safe, effective analgesia, with minimal side effects. Many additives to local anesthetics used to prolong the duration of analgesia for peripheral nerve blocks have been studied as dexamethasone, dexmedetomidine Dexmedetomidine is a lipophilic α2 agonist derivative with a higher affinity for α2-receptors than clonidine (α2: α1 specificity ratio is 200:1 for clonidine and 1600:1 for dexmedetomidine). It has sedative, analgesic, and sympatholytic effects that blunt many of the cardiovascular responses seen during the perioperative period. Animal and human studies have shown safety and efficacy of adding dexmedetomidine to local anesthetics in various regional anesthetic procedures. The addition of dexmedetomidine to bupivacaine in TAP block achieves better local anesthesia and provides better pain control postoperatively without any major side-effects.
Dexamethasone is a systemic glucocorticoid that improves the quality of recovery after surgery by reducing pain, nausea, and vomiting. When added to local anesthetics as an adjuvant in peripheral blocks, it prolongs the analgesia time. Mechanism of action may be through the anti-inflammatory action, the increase of the local efficiency, and to slow down of the absorption.
Objective:
The objective is to compare and evaluate efficacy and safety of dexmedetomidine and dexamethasone as a local anesthetic adjuvant to bupivacaine in ultrasound-guided TAP block for patients scheduled for total abdominal hysterectomies.
Detailed description
PATIENTS AND METHODS:
This study will be performed on Fifty-four adult patients who will be undergone an abdominal hysterectomy after obtaining the approval of the local ethical committee and scientific institutional review board. written informed consents will be signed from each patient before enrollment and randomization into the study.
The patients will be randomly allocated to receive either a mixture of bupivacaine and dexamethasone 8 mg (group A, 27 patients) or a mixture of bupivacaine and dexmedetomidine 80 µg (group B, 27 patients). Randomization will be performed by using a computer-generated random number list. The random number for each patient will be concealed in opaque sealed envelope which will be opened by the investigators shortly after the admission of the patient into the operation room. The investigators sharing in the patients care and data acquisition will be blinded to groups allocation till full completion of statistical analysis.
Preoperative preparation:
Visual analog scale (VAS) will be explained to all the patients on preoperative visit (0-10 cm, in which 0 cm = no pain and 10 cm = worst pain) and the compulsory investigations according to the regular institutional protocol will be done [electrocardiogram (ECG), complete blood count (CBC), blood sugar level, serum urea and creatinine, liver function tests, and coagulation profile].
On the day of surgery, intravenous (IV) access will be inserted. The patient will be administered midazolam 0.03 mg/kg, metoclopramide 10 mg slowly, ranitidine 50 mg, and cefotaxime 1 gm intravenously (IV) as premedications.
Anesthetic technique:
All the patients will be received a standard general anesthesia with standard monitoring [ECG, noninvasive blood pressure (NIBP), capnography and pulse oximetry]. Anesthesia will be induced by using fentanyl 1μg/kg, propofol 1.5-2 mg/kg and Atracurium 0.5 mg/kg will be used for muscle relaxation to facilitate endotracheal intubation by cuffed endotracheal tube (internal diameter = 7 mm).
After induction of anesthesia and under a complete aseptic condition, the TAP blocks will be performed by the attending anesthesiologists who will not participate in this trial under real-time ultrasound guidance (Philips ClearVue 350 Ultrasound Machine, Philips healthcare, USA). At the level of the umbilicus, the high-frequency ultrasound linear array probe (L4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. Identification of the external oblique, the internal oblique, and the transversus abdominis muscles and localization of the fascial plane between the internal oblique and the transversus abdominis muscle that appeared as a hypoechoic line will be done. The local anesthetic solution mixture will be injected with short bevel needle (22 Gauge, 90 mm sonoplex stim cannula, Pajunk® GmbH, Geisingen, Germany) under real-time ultrasound guidance after negative aspiration to avoid intravascular injection. The local anesthetic solution mixture will be observed separating the fascial plane during injection. The TAP block will be then performed on the opposite side, using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to group A (dexamethasone group, 27 patients), the local anesthetic solution mixture consisted of a total volume of 40 ml bupivacaine 0.25 % and dexamethasone 8 mg, 20 ml injected on each side. Dexamethasone sodium phosphate (Epidron®, EIPICO, Cairo, Egypt) is supplied in 4 mg/ml ampule. For the patients randomized to group B (dexmedetomidine group, 27 patients), the local anesthetic solution mixture consisted of a total volume of 40 ml bupivacaine 0.25 % and dexmedetomidine 80 µg, 20 ml injected on each side. Dexmedetomidine hydrochloride (Precedex®, manufactured by Hospira, Inc. Lake Forest, IL, and USA) is supplied in 100 μg/ml ampule. the local anesthetic solution mixture will be prepared and coded by independent attending anesthesiologists who will not share in data collection or in patients care.
Anesthesia will be maintained with isoflurane 1.5 volume % and Atracurium 0.1 mg/kg will be administered as a maintenance dose every 30 minutes until completion of the procedure. Ventilation parameters will be adjusted as follows: tidal volume (TV) = 4-8 ml/kg, positive end-expiratory pressure (PEEP) = 5 cm H2O, respiratory rate (RR) = 12/min then it will be adjusted to maintain end-tidal CO2 between 35-40 mmHg, and fraction of inspired oxygen (FiO2) = 0.5-0.6.
Fentanyl 0.5μg/kg will be given intraoperatively when either heart rate or NIBP increased by more than 20% of the basal records and could be repeated till the desired effect. After completion of the procedure, anesthesia will be discontinued and tracheal extubation will be done once the extubation criteria will be fulfilled. The patients then will be transferred to the post-anesthesia care unit (PACU) for two hours' observation period. The patients will be discharged to the ward after fulfilling the discharge criteria based on modified Aldrete score ≥ 9.(17) As a part of standardized regular institutional postoperative pain control policy, Acetaminophen 1 gm every 6 hours by IV infusion and ketorolac 30 mg diluted in 100 ml normal saline through IV infusion over 20 minutes every 8 hours will be administered. Patients with VAS ≥ 5 received morphine sulfate IV at a bolus dose of 2-5 mg increments with a maximum dose of 15 mg per 4 hours or 45 mg per 24 hours. The criteria to stop morphine titration will be reasonable pain control or the patient became sedated (Ramsay sedation scale >2). Furthermore, respiratory rate < 10 / min, Oxygen saturation < 95%, or development of serious adverse effects (allergy, marked itching, excessive vomiting, and hypotension with systolic blood pressure ≤ 20% of baseline readings).
STATISTICAL ANALYSIS:
The normally distributed numerical data will be presented as mean (SD) and differences between groups will be compared using Student's t-tests. Continuous data with skewness and kurtosis as well as the ordinal data will be presented as median (interquartile range[IQR]) and compared for significance by using the Mann-Whit¬ney U test. The Kolmogorov-Smirnov test will be implemented to check the normality of Continuous data distribution (P ≤ 0.05). Categorical data will be presented as proportions and will be compared for significance by using the chi-square test. Fisher's exact test will be used instead if the minimum expected cell count less than five. We will use the log-rank test and Kaplan-Meier curves to compare data measuring time to an event. The level P ≤ 0.05 will be considered the cut-off value for significance. Statistical analysis will be performed using the statistical package for the social sciences (SPSS) version 16 (SPSS Inc., Chicago, IL, USA).
The sample size of 22 patients per group was found acceptable to detect a difference of 65 minutes between both groups in time for the first request of analgesia (primary outcome), assuming α = 0.05 (two tail), β = 0.2 (80 % power), and the standard deviation = 75 minutes (derived from Ammar et al. 2012). Recruitment of 27 patients per group will be done to account for possible data loss. Sample size calculation will be done by using G*Power software version 3.1.9.2 (Institute of Experimental Psychology, Heinrich Heine University, Dusseldorf, Germany).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dexamethasone arm (group A) | Active comparator | Drug: dexamethasone 8 mg, Drug: Bupivacaine 0.25% Injectable SolutionThe local anesthetic solution mixture consists of dexamethasone 8 mg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 2 ml dexamethasone = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia. |
| Dexmedetomidine arm (group B) | Active comparator | Drug: dexmedetomidine 80 µg, Drug: Bupivacaine 0.25% Injectable SolutionThe local anesthetic solution mixture consists of dexmedetomidine 80 µg in Bupivacaine 0.25% Injectable Solution to a total volume of 40 ml (19 ml bupivacaine 0.5 % + 19 ml normal saline + 80 µg dexmedetomidine in 2 ml = 40ml). 20 ml of the local anesthetic solution mixture will be injected on each side.The Transversus abdominis Plane (TAP) block will be performed once after induction of anesthesia. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- American society of anesthesiologists (ASA) physical status grade 1 and 2.
- Age of 18 years and more.
- Patients who will be scheduled for total abdominal hysterectomies.
Key exclusion criteria (9 listed)
- Patient refusal.
- Body mass index (BMI) > 40.
- Patients with chronic pain and those using chronic analgesic medications.
- Coagulopathy.
- Allergy to the study drugs.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| dexamethasone 8 mgAlso: Dexamethasone 4 mg/mlAt the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both side using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexamethasone group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexamethasone 8 mg. | Drug | Dexamethasone arm (group A) |
| dexmedetomidine 80 µgAlso: precedex 100 µg/mlAt the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both sides using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexmedetomidine group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexmedetomidine 80 µg. | Drug | Dexmedetomidine arm (group B) |
| Bupivacaine 0.25% Injectable SolutionAlso: Marcaine 0.25%38 ml of the solution will be prepared to be used in transversus abdominis plane block | Drug | Dexamethasone arm (group A), Dexmedetomidine arm (group B) |
Primary outcome
Time to first request of analgesia
Time frame: During the 24 hours postoperatively
The time passed till the patient request an analgesic dose
36 secondary outcomes
Visual Analog Scale (VAS) at rest
Time frame: Assesment will be done at 2 hours postoperatively
Visual Analog Scale (VAS) at rest
Time frame: Assesment will be done at 4 hours postoperatively
Visual Analog Scale (VAS) at rest
Time frame: Assesment will be done at 6 hours postoperatively
Visual Analog Scale (VAS) at rest
Time frame: Assesment will be done at 12 hours postoperatively
Visual Analog Scale (VAS) at rest
Time frame: Assesment will be done at 18 hours postoperatively
Visual Analog Scale (VAS) at rest
Time frame: Assesment will be done at 24 hours postoperatively
Visual Analog Scale (VAS) at rest
Time frame: Assesment will be done at 48 hours postoperatively
Visual Analog Scale (VAS) on movement
Time frame: Assesment will be done at 2 hours postoperatively
Visual Analog Scale (VAS) on movement
Time frame: Assesment will be done at 4 hours postoperatively
Visual Analog Scale (VAS) on movement
Time frame: Assesment will be done at 6 hours postoperatively
Visual Analog Scale (VAS) on movement
Time frame: Assesment will be done at 12 hours postoperatively
Visual Analog Scale (VAS) on movement
Time frame: Assesment will be done at 18 hours postoperatively
Visual Analog Scale (VAS) on movement
Time frame: Assesment will be done at 24 hours postoperatively
Visual Analog Scale (VAS) on movement
Time frame: Assesment will be done at 48 hours postoperatively
Interval doses of consumed morphia
Time frame: During 0 - 2 hours postoperatively
Interval doses of consumed morphia
Time frame: During 2 - 4 hours postoperatively
Interval doses of consumed morphia
Time frame: During 4 - 6 hours postoperatively
Interval doses of consumed morphia
Time frame: During 6 - 12 hours postoperatively
Interval doses of consumed morphia
Time frame: During 12 - 18 hours postoperatively
Interval doses of consumed morphia
Time frame: During 18 - 24 hours postoperatively
Interval doses of consumed morphia
Time frame: During 24 - 48 hours postoperatively
Cumulative doses of consumed morphia
Time frame: During the 24 hours postoperatively
Intraoperative fentanyl consumption
Time frame: At the end of surgical procedure
Nausea
Time frame: During the 48 hour postoperatively
Vomiting
Time frame: During the 48 hour postoperatively
Sedation score
Time frame: At 2 hours postoperatively
Sedation score
Time frame: At 4 hours postoperatively
Sedation score
Time frame: At 6 hours postoperatively
Sedation score
Time frame: At 12 hours postoperatively
Sedation score
Time frame: At 18 hours postoperatively
Sedation score
Time frame: At 24 hours postoperatively
Sedation score
Time frame: At 48 hours postoperatively
Hypotension
Time frame: During intraoperative period
Hypotension
Time frame: During 48 hours postoperatively
Bradycardia
Time frame: During intraoperative period
Bradycardia
Time frame: During 48 hours postoperatively
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jun 2018.
- Background: PubMed 23162395Ammar AS, Mahmoud KM. Effect of adding dexamethasone to bupivacaine on transversus abdominis plane block for abdominal hysterectomy: A prospective randomized controlled trial. Saudi J Anaesth. 2012 Jul;6(3):229-33. doi: 10.4103/1658-354X.101213.
- Background: PubMed 24843325Almarakbi WA, Kaki AM. Addition of dexmedetomidine to bupivacaine in transversus abdominis plane block potentiates post-operative pain relief among abdominal hysterectomy patients: A prospective randomized controlled trial. Saudi J Anaesth. 2014 Apr;8(2):161-6. doi: 10.4103/1658-354X.130683.
- Background: PubMed 23587874Abdallah FW, Brull R. Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis. Br J Anaesth. 2013 Jun;110(6):915-25. doi: 10.1093/bja/aet066. Epub 2013 Apr 15.
- Background: PubMed 26677342Gadsden J, Ayad S, Gonzales JJ, Mehta J, Boublik J, Hutchins J. Evolution of transversus abdominis plane infiltration techniques for postsurgical analgesia following abdominal surgeries. Local Reg Anesth. 2015 Dec 10;8:113-7. doi: 10.2147/LRA.S96253. eCollection 2015.
- Individual participant dataSharing planned: No
Related trials for Postoperative Pain
RecruitingPhase 4
Anrikefon-based Patient-controlled Intravenous Analgesia Following Laparoscopic Surgery
Laparoscopic Surgery, Visceral Pain, Postoperative
Recruiting
NOL Guided Analgesia During Elective Laparoscopic Surgery Under General Anesthesia
Intraoperative Analgesia
Recruiting
Aescin-Based Herbal Extract (Reparil) for Postoperative Sequelae After Mandibular Third Molar Surgery
Postoperative Pain, Facial Swelling
Recruiting
Effect of Ultrasonic and Diode Laser Activated Irrigation on Postoperative Pain Following Root Canal Treatment
Symptomatic Irreversible Pulpitis and Symptomatic Apical Periodontitis
Not yet recruiting
Opioid Reduction and Enhanced Recovery in Orthopaedic Surgery (OREOS)-Knee
Knee Arthroplasty, Total, Partial Knee Arthroplasty
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hany M Yassin, MD principal investigator
Fayoum University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing dexamethasone 8 mg, dexmedetomidine 80 µg and Bupivacaine 0.25% Injectable Solution in people with Postoperative Pain, run by Fayoum University Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Jun 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to first request of analgesia (time frame: During the 24 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03064633, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2018.